Patents by Inventor Jan Weiler
Jan Weiler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10023862Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.Type: GrantFiled: January 8, 2013Date of Patent: July 17, 2018Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Brian Richard Bettencourt, David Anton Bumcrot, Dieter Huesken, Satyanarayana Kuchimanchi, Stuart Milstein, Michael Ray Schlabach, Jr., Frank Peter Stegmeier, Markus Warmuth, Jan Weiler
-
Publication number: 20180153919Abstract: The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.Type: ApplicationFiled: September 7, 2016Publication date: June 7, 2018Inventors: Brian Bettencourt, Stuart Milstein, Ivanka Toudjarska, Earl McDonald, Michael Schlabach, JR., Frank P. Stegmeier, Markus Warmuth, Kalyani Gampa, Dieter Huesken, Mark Stump, Jan Weiler, Zainab Jagani
-
Patent number: 9988627Abstract: The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap.Type: GrantFiled: October 6, 2014Date of Patent: June 5, 2018Assignee: NOVARTIS AGInventors: Jeremy Lee Baryza, Marcel Blommers, William Chutkow, Cesar Fernandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng Zhu
-
Publication number: 20180100151Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: ApplicationFiled: December 7, 2017Publication date: April 12, 2018Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Heusken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Patent number: 9868949Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: GrantFiled: February 27, 2014Date of Patent: January 16, 2018Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Heusken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Publication number: 20170298354Abstract: The present disclosure relates to methods of treating heat stock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: ApplicationFiled: May 5, 2017Publication date: October 19, 2017Inventors: Jinyun Chen, Kalyani Gampa, Dieter Huesken, Frank Stegmeier, Mark Stump, Chandra Vargeese, Jan Weiler, Wenlai Zhou
-
Publication number: 20170175116Abstract: Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.Type: ApplicationFiled: December 19, 2016Publication date: June 22, 2017Inventors: Manuela Polydoro Ofengeim, Jan Weiler
-
Publication number: 20170137814Abstract: The present disclosure relates to compositions and methods for treating APOC3-related diseases such as: hypertriglyceridemia (e.g., Type V Hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including Type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a RNAi agent to APOC3.Type: ApplicationFiled: January 11, 2017Publication date: May 18, 2017Inventors: Jan Weiler, William Chutkow, Jeremy Lee Baryza, Andrew Krueger, Junping Zhao
-
Publication number: 20160311907Abstract: Compositions and methods relating to regulatable chimeric antigen receptors (RCARs), where the intracellular signaling or proliferation of the RCAR can be controlled to optimize the use of an RCAR-expressing cell to provide an immune response, are provided. For example, a RCAR can comprise a dimerization switch that, upon the presence of a dimerization molecule, can couple an intracellular signaling domain to an extracellular recognition element, e.g., an antigen binding domain, an inhibitory counter ligand binding domain, or costimulatory ECD domain. An RCAR can be engineered to include an appropriate antigen binding domain that is specific to a desired antigen target and used in the treatment of a disease.Type: ApplicationFiled: December 19, 2014Publication date: October 27, 2016Inventors: Jennifer Brogdon, Boris Engels, David Jonathan Glass, Brian Granda, John Hastewell, Andreas Loew, Joan Mannick, Michael Milone, Leon Murphy, William Raj Sellers, Huijuan Song, Brian Edward Vash, Jan Weiler, Qilong Wu, Li Zhou
-
Publication number: 20160304863Abstract: The disclosure relates to novel compounds and compositions comprising a RNAi agent comprising a novel compound as a 3? end cap. The disclosure also relates to processes for making such compositions, and methods and uses of such compositions, e.g., to mediate RNA interference.Type: ApplicationFiled: October 1, 2014Publication date: October 20, 2016Inventors: Jeremy Lee BARYZA, Marcel BLOMMERS, Cesar FERNANDEZ, Erin GENO, Alvar GOSSERT, Paulette GREENIDGE, Dieter HUESKEN, Juerg HUNZIKER, Francois Jean-Charles NATT, Anup PATNAIK, Andrew PATTERSON, Jean-Michel Rene RONDEAU, Jan WEILER, Meicheng ZHU
-
Publication number: 20160244756Abstract: The disclosure relates to compositions comprising a RNAi agent having a novel format including a spacer subunit. The disclosure relates to compositions comprising a RNAi agent having a novel format: an 18-mer format with at least one internal spacer. These RNAi agents comprise a first and a second 18-mer strand, wherein the first strand is 18 ribonucleotides or 18 total ribonucleotides and spacer subunit(s), and the second strand is 18 total ribonucleotides and spacer subunit(s), wherein: each spacer subunit consists of: (a) a phosphate or modified internucleoside linker and (b) a spacer; a spacer subunit can be at any position in the strand; the two strands form a duplex with at least one blunt end; and the 3 end of one or both strands terminates in a phosphate or modified internucleoside linker and further comprises, in 5 to 3 order: a second spacer; a second phosphate or modified internucleoside linker, and a 3 end cap.Type: ApplicationFiled: October 6, 2014Publication date: August 25, 2016Inventors: Jeremy Lee BARYZA, Marcel BLOMMERS, William CHUTKOW, Cesar FERNANDEZ, Erin GENO, Alvar GOSSERT, Paulette GREENIDGE, Dieter HUESKEN, Juerg HUNZIKER, Francois Jean-Charles NATT, Anup PATNAIK, Andrew PATTERSON, Jean-Michel Rene RONDEAU, Jan WEILER, Meicheng ZHU
-
Publication number: 20160215288Abstract: The disclosure relates to compositions comprising a HBV RNAi agent. In some embodiments, the HBV RNAi agent comprises a sense and an anti-sense strand, each strand being an 18-mer and the strands together forming a blunt-ended duplex, wherein the 3? end of at least one strand terminates in a phosphate or modified internucleoside linker and further comprises, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. In some embodiments, the 3? end of both the sense and anti-sense strand further comprise, in 5? to 3? order: a spacer; a second phosphate or modified internucleoside linker; and a 3? end cap. The two strands can have the same or different spacers, phosphates or modified internucleoside linkers, and/or 3? end caps. The strands can be ribonucleotides, or, optionally, one or more nucleotide can be modified or substituted. Optionally, at least one nucleotide comprises a modified internucleoside linker.Type: ApplicationFiled: September 30, 2014Publication date: July 28, 2016Inventors: Jeremy Lee Baryza, Marcel Blommers, Cesar Femandez, Erin Geno, Alvar Gossert, Paulette Greenidge, Dieter Huesken, Juerg Hunziker, Francois Jean-Charles Natt, Anup Patnaik, Andrew Patterson, Jean-Michel Rene Rondeau, Jan Weiler, Meicheng zhu, Meghan Holdorf
-
Publication number: 20160032284Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer, autoimmune and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.Type: ApplicationFiled: August 30, 2012Publication date: February 4, 2016Applicant: Arrowhead Research CorportationInventors: Jinyun CHEN, Kalyani GAMPA, Dieter HUESKEN, Frank STEGMEIER, Mark STUMP, Chandra VARGEESE, Jan WEILER, Wenlai ZHOU
-
Publication number: 20160010089Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.Type: ApplicationFiled: February 27, 2014Publication date: January 14, 2016Inventors: Brian Bettencourt, Shanthi Ganesh, Elizabeth George, Dieter Huesken, Stuart Milstein, Jonathan Solomon, Emily Thomas, Ivanka Toudjarska, Jennifer Tullai, Jan Weiler
-
Publication number: 20150291954Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-Catenin-related diseases such as adenomatous polyposis of the colon, colorectal cancer, basal cell carcinoma, breast cancer, kidney cancer, Wilms tumors, medulloblastoma, ovarian cancer, adrenocortical tumors, gastric cancer, liver cancer, melanoma, pancreatic cancers, prostate cancer, renal cancer, ectopic teeth and taste papillae, skin cancer, pilomatrixoma, anaplastic thyroid carcinoma, and uterine carcinosarcoma, oligodontia, osteoporosis, ageing, degenerative diseases, bedsores, chronic wounds and impaired wound healing, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to Beta-Catenin.Type: ApplicationFiled: January 8, 2013Publication date: October 15, 2015Applicant: NOVARTIS AGInventors: Brian Richard Bettencourt, David Anton Bumcrot, Dieter Huesken, Satyanarayana Kuchimanchi, Stuart Milstein, Michael Ray Schlabach, JR., Frank Peter Stegmeier, Markus Warmuth, Jan Weiler
-
Publication number: 20150238515Abstract: The present disclosure relates to RNAi agents useful in methods of treating KRAS-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a RNAi agent to KRAS.Type: ApplicationFiled: April 30, 2013Publication date: August 27, 2015Inventors: Brian Bettencourt, Stuart Milstein, Ivanka Jarska, Earl McDonald, Michael Schlabach, JR., Frank P. Stegmeier, Markus Warmuth, Kalyani Gampa, Dieter Huesken, Mark Stump, Jan Weiler, Zainab Jagani
-
Publication number: 20120114744Abstract: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.Type: ApplicationFiled: January 18, 2012Publication date: May 10, 2012Applicant: NOVARTIS AGInventors: Iwan BEUVINK, Jonathan HALL, Jan WEILER, Christian SCHNELL, Matthias MUELLER, Martina SCHINKE-BRAUN, Fabrizio SERLUCA
-
Publication number: 20120041052Abstract: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.Type: ApplicationFiled: August 9, 2011Publication date: February 16, 2012Applicant: NOVARTIS AGInventors: Iwan BEUVINK, Jonathan HALL, Jan WEILER, Christian Rene SCHNELL, Matthias MUELLER, Martina SCHINKE-BRAUN, Fabrizio SERLUCA
-
Patent number: 8097716Abstract: The present invention relates to double-stranded RNA compounds with at least one blunt end comprising at least one 3?-end of formula wherein X is O or S R1 and R2 are independently OH, NH2, SH, alkyl, aryl, alkyl-aryl, aryl-alkyl, where alkyl, aryl, alkyl-aryl, aryl-alkyl can be substituted by additional heteroatoms and functional groups, preferably a heteroatom selected from the group of N, O, or S or a functional group selected from the group OH, NH2, SH, carboxylic acid or ester; or R1 and R2 may be of formula Y-Z where Y is O, N, S and Z is H, alkyl, aryl, alkyl-aryl, aryl-alkyl, where alkyl, aryl, alkyl-aryl, aryl-alkyl can be substituted by additional heteroatoms, preferably a heteroatom selected from the group of N, O, or S; and wherein said double-stranded RNA mediates RNA interference.Type: GrantFiled: December 18, 2008Date of Patent: January 17, 2012Assignee: Novartis AGInventors: Jan Weiler, Jonathan Hall, Jean-Charles Bologna, Francois Jean-Charles Natt, Robert Haner
-
Publication number: 20100280094Abstract: The present invention relates to a novel microRNA, mir-208-2, implicated in muscular and cardiovascular disorders. The present invention also relates to oligonucleotide therapeutic agents (antisense oligonucleotides and/or double stranded oligonucleotides such as dsRNA) and their use in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.Type: ApplicationFiled: December 13, 2007Publication date: November 4, 2010Inventors: Iwan Beuvink, Jonathan Hall, Jan Weiler, Christian Schnell, Mathias Mueller, Martina Schinke-Braun, Fabrizio Serluca